Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
<p><strong>Aim:</strong> Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. </p> <p><strong>Patients & methods:</strong> Longitudinal QoL was assessed using...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Future Medicine
2020
|